- Home
- SAGE vs DCTH Comparison
SAGE vs DCTH Comparison
Compare SAGE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAGE
- DCTH
- Stock Information
- Founded
- SAGE 2010
- DCTH 1988
- Country
- SAGE United States
- DCTH United States
- Employees
- SAGE N/A
- DCTH N/A
- Industry
- SAGE Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- SAGE Health Care
- DCTH Health Care
- Exchange
- SAGE Nasdaq
- DCTH Nasdaq
- Market Cap
- SAGE 415.0M
- DCTH 518.0M
- IPO Year
- SAGE 2014
- DCTH N/A
- Fundamental
- Price
- SAGE $6.71
- DCTH $14.36
- Analyst Decision
- SAGE Hold
- DCTH Strong Buy
- Analyst Count
- SAGE 19
- DCTH 4
- Target Price
- SAGE $9.88
- DCTH $22.75
- AVG Volume (30 Days)
- SAGE 934.8K
- DCTH 381.8K
- Earning Date
- SAGE 04-29-2025
- DCTH 05-08-2025
- Dividend Yield
- SAGE N/A
- DCTH N/A
- EPS Growth
- SAGE N/A
- DCTH N/A
- EPS
- SAGE N/A
- DCTH N/A
- Revenue
- SAGE $47,404,000.00
- DCTH $53,850,000.00
- Revenue This Year
- SAGE $100.64
- DCTH $128.78
- Revenue Next Year
- SAGE $70.19
- DCTH $54.07
- P/E Ratio
- SAGE N/A
- DCTH N/A
- Revenue Growth
- SAGE N/A
- DCTH 1068.87
- 52 Week Low
- SAGE $4.62
- DCTH $5.30
- 52 Week High
- SAGE $14.56
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- SAGE 35.06
- DCTH 67.56
- Support Level
- SAGE $7.23
- DCTH $11.38
- Resistance Level
- SAGE $7.63
- DCTH $12.49
- Average True Range (ATR)
- SAGE 0.29
- DCTH 0.57
- MACD
- SAGE -0.09
- DCTH 0.22
- Stochastic Oscillator
- SAGE 0.38
- DCTH 91.61
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.